These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23496785)

  • 21. Proteomic approaches in lung cancer biomarker development.
    Cho JY; Sung HJ
    Expert Rev Proteomics; 2009 Feb; 6(1):27-42. PubMed ID: 19210125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-resolution biomarker discovery: Moving from large-scale proteome profiling to quantitative validation of lead candidates.
    Hewel JA; Emili A
    Proteomics Clin Appl; 2008 Oct; 2(10-11):1422-34. PubMed ID: 21136791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood and plasma-based proteomic biomarker research in Alzheimer's disease.
    Lista S; Faltraco F; Prvulovic D; Hampel H
    Prog Neurobiol; 2013; 101-102():1-17. PubMed ID: 22743552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alzheimer's disease cerebrospinal fluid biomarker discovery: a proteomics approach.
    D'Ascenzo M; Relkin NR; Lee KH
    Curr Opin Mol Ther; 2005 Dec; 7(6):557-64. PubMed ID: 16372405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteomics: new technologies and clinical applications.
    Latterich M; Abramovitz M; Leyland-Jones B
    Eur J Cancer; 2008 Dec; 44(18):2737-41. PubMed ID: 18977654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Entering the era of proteomics in rheumatology.
    Lambrecht S; Deforce D; Elewaut D
    Expert Opin Drug Discov; 2006 Nov; 1(6):539-48. PubMed ID: 23506065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From bench to bedside: discovery of ovarian cancer biomarkers using high-throughput technologies in the past decade.
    Leung F; Diamandis EP; Kulasingam V
    Biomark Med; 2012 Oct; 6(5):613-25. PubMed ID: 23075239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy.
    Fredolini C; Liotta LA; Petricoin EF
    Crit Rev Clin Lab Sci; 2010; 47(3):125-38. PubMed ID: 20858067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selected highlights of the Third Annual Biomarkers Congress: from discovery to validation in the drug development arena.
    Currid CA; Gallagher WM
    Expert Opin Med Diagn; 2008 Sep; 2(9):1091-4. PubMed ID: 23495928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Translational proteomics: developing a predictive capacity -- a review.
    Rice GE; Georgiou HM; Ahmed N; Shi G; Kruppa G
    Placenta; 2006 Apr; 27 Suppl A():S76-86. PubMed ID: 16434096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteomics in prostate cancer biomarker discovery.
    Larkin SE; Zeidan B; Taylor MG; Bickers B; Al-Ruwaili J; Aukim-Hastie C; Townsend PA
    Expert Rev Proteomics; 2010 Feb; 7(1):93-102. PubMed ID: 20121479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative proteomic approaches for biomarker discovery.
    Hu Z; Hood L; Tian Q
    Proteomics Clin Appl; 2007 Sep; 1(9):1036-41. PubMed ID: 21136755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in capillary electrophoresis-based proteomic techniques for biomarker discovery.
    Fang X; Balgley BM; Lee CS
    Electrophoresis; 2009 Dec; 30(23):3998-4007. PubMed ID: 19960464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarker discovery and validation: technologies and integrative approaches.
    Ilyin SE; Belkowski SM; Plata-Salamán CR
    Trends Biotechnol; 2004 Aug; 22(8):411-6. PubMed ID: 15283986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery.
    Matta A; Ralhan R; DeSouza LV; Siu KW
    Mass Spectrom Rev; 2010; 29(6):945-61. PubMed ID: 20945361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CE-MS in biomarker discovery, validation, and clinical application.
    Mischak H; Schanstra JP
    Proteomics Clin Appl; 2011 Feb; 5(1-2):9-23. PubMed ID: 21280234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical perspectives of high-resolution mass spectrometry-based proteomics in neuroscience: exemplified in amyotrophic lateral sclerosis biomarker discovery research.
    Ekegren T; Hanrieder J; Bergquist J
    J Mass Spectrom; 2008 May; 43(5):559-71. PubMed ID: 18416436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical proteomics: discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches--a prostate cancer perspective.
    Matharoo-Ball B; Ball G; Rees R
    Vaccine; 2007 Sep; 25 Suppl 2():B110-21. PubMed ID: 17916461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advanced proteomic technologies for cancer biomarker discovery.
    Wong SC; Chan CM; Ma BB; Lam MY; Choi GC; Au TC; Chan AS; Chan AT
    Expert Rev Proteomics; 2009 Apr; 6(2):123-34. PubMed ID: 19385940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.